The American Society of Transplantation Online Transplant Infectious Diseases Library
Full Library 1,578 resources
-
Recurrent urinary tract infections (UTIs) are common, especially in women. When oral antimicrobial prophylaxis is ineffective or not possible due to allergies or antimicrobial resistance, intravesical aminoglycoside instillations (IAIs) are a non-systemic alternative.To assess treatment satisfaction, long-term safety and efficacy of IAIs for recurrent UTI.We conducted a cohort study using data collected between January 2013 and June 2022 at the Leiden University Medical Center. Adult...
-
In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuation, predominately in haploidentical HCT recipients, without any associations with CMV-DNAemia under letermovir.
-
Eculizumab, a recombinant humanized monoclonal antibody (mAb), is used for the treatment of patients (both adults and children) with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This mAb binds to complement protein 5 (C5), thereby inhibiting its cleavage. On the other hand, one of the C5 cleavage products, C5a, is a potent anaphylatoxin with proinflammatory properties, involved in antimicrobial surveillance. Administration of eculizumab has been reported to...
-
Respiratory viral infections (RVIs) are of major clinical importance in immunocompromised patients and represent a substantial cause of morbidity and mortality in patients with hematologic malignancies and those who have undergone hematopoietic cell transplantation. Similarly, patients receiving immunotherapy with CD19-targeted chimeric antigen receptor–modified T cells, natural killer cells, and genetically modified T-cell receptors are susceptible to RVIs and progression to lower...
-
Conclusion: This is the first reported failure of rabies PEP in the Western Hemisphere using a cell culture vaccine. Host-mediated primary vaccine failure attributed to previously unrecognized D impaired immunity is the most likely explanation for this breakthrough infection. Clinicians should consider measuring rabies neutralizing antibody titers after completion of PEP if there is E any suspicion for immunocompromise.
-
Severely immunocompromised patients are at risk for prolonged or relapsed COVID-19 leading to increased morbidity and mortality. We aimed to evaluate efficacy and safety of combination treatment in immunocompromised COVID-19 patients.We included all immunocompromised patients with prolonged/relapsed COVID-19 treated with combination therapy with two antivirals (remdesivir plus nirmatrelvir/ritonavir, or molnupiravir in case of renal failure) plus, if available, anti-spike monoclonal...
-
Mycoplasma hominis and Ureaplasma species infections in the post-transplant setting are believed to be donor-derived and can be associated with poor outcomes. Difficulty in culturing and identifying these organisms is a significant barrier to diagnosis and early intervention. Tetracyclines, macrolides and fluoroquinolones are the mainstay treatments to cure these infections; however, there are increasing reports of antibiotic resistance. In this case series, we report our single-centre...
-
Posttransplant lymphoproliferative disorder (PTLD) represents a heterogeneous group of lymphoproliferative diseases occurring in the setting of immunosuppression following hematopoietic stem cells transplant and solid organ transplantation. Despite its overall low incidence, PTLD is a serious complication following transplantation, with a mortality rate as high as 50% in transplant recipients. Therefore, it is important to establish for each transplant recipient a personalized risk...
-
Invasive fungal diseases (IFDs), in particular invasive mold infections, still pose considerable problems in the care of children and adolescents treated for cancer or undergoing hematopoietic cell transplantation. As these infections are difficult to diagnose, and the outcomes for IFDs are still unsatisfactory, antifungal prophylaxis has become an important strategy in the clinical setting. Antifungal prophylaxis is indicated in patients at high risk for IFD, which is commonly defined as a...
-
Coccidioidomycosis is a fungal infection with a range of clinical manifestations. Currently used antifungal agents exhibit variable efficacy and toxicity profiles necessitating evaluation of additional therapeutic options. Improvement was observed in the majority of patients treated with isavuconazole, with clinical failures observed only in those with coccidioidal meningitis.
-
We sought to compare the outcomes of patients treated with intravenous (IV)-only vs. oral transitional antimicrobial therapy for infective endocarditis (IE) after implementing a new Expected Practice within The Los Angeles County Department of Health Services (LAC DHS).We conducted a multi-centered, retrospective cohort study of adults with definite or possible IE treated with IV-only vs. oral therapy at the three acute care, public hospitals in the LAC DHS system between December 2018 to...
-
Rationale Nontuberculous mycobacterial (NTM) diseases are difficult-to-treat infections, especially in lung transplant (LTx) candidates. Currently, there is a paucity of recommendations on the management of NTM infections in LTx, focusing on Mycobacterium avium complex (MAC), M. abscessus and M. kansasii. Methods Pulmonologists, infectious disease specialists, LTx surgeons and Delphi experts with expertise in NTM were recruited. A patient representative was also invited. Three questionnaires...
-
We report Babesia microti genomic sequences with multiple mutations in the atovaquone-target region of cytochrome b, including a newly identified Y272S mutation, plus 1 mutation of undetermined significance in the azithromycin-associated ribosomal protein L4. The parasite was sequenced from an immunocompromised patient on prophylactic atovaquone for Pneumocystis pneumonia before diagnosis of babesiosis.
-
Abstract Adoptively transferred virus-specific T cells (VSTs) have shown remarkable safety and efficacy for the treatment of virus-associated diseases and malignancies in hematopoietic stem cell transplant (HSCT) recipients, for whom VSTs are derived from the HSCT donor. Autologous VSTs have also shown promise for the treatment of virus-driven malignancies outside the HSCT setting. In both cases, VSTs are manufactured as patient-specific products, and the time required for...
-
People with human immunodeficiency virus (HIV) with and without hepatitis C virus (HCV) coinfection had poor outcomes after liver transplant (LT). Integrase strand transfer inhibitors (INSTIs) and direct-acting antivirals (DAAs) have changed the treatment landscape for HIV and HCV, respectively, but their impact on LT outcomes remains unclear.This retrospective analysis of adults with HIV monoinfection (n = 246) and HIV/HCV coinfection (n = 286) who received LT compared mortality in patients...
-
Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown.Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant...
-
Gut microbiota injury in allogeneic HCT recipients has been associated with adv...
Filter by our tag
GUIDELINES
- AASLD Guidelines (9)
- AST Guidelines 2019 (44)
- ASTCT Guidelines (14)
- ECIL Guidelines (20)
- ESCMID Guidelines (25)
- IDSA Guidelines (45)
- ISHLT Guidelines (12)
- TTS Guidelines (2)
- WikiGuidelines (3)
TEXTBOOKS
CORE CURRICULUM
- INTRO LVAD AND MCSS (4)
- INTRO MALIGNANT HEME, HSCT, CAR-T (10)
- INTRO SOLID ORGAN TRANSPLANT (20)
- ORGANISMS (41)
-
SYNDROMES
(16)
- CNS (2)
- Diarrhea (3)
- Neutropenic Fever (2)
- Pneumonia (7)
- UTI (2)
ORGANISMS
-
BACTERIA
(160)
- C. difficile (25)
- Legionella (1)
- MDR GNR (37)
- MRSA (7)
- Mycoplasma and Ureaplasma (11)
- Nocardia (11)
- Non-tuberculous Mycobacteria (27)
- Syphilis (6)
- Tuberculosis (35)
- VRE (8)
-
FUNGI
(218)
- Aspergillus (57)
- Candida (41)
- Cryptococcus (29)
- Dimorphic mycoses (42)
- Mucormycosis (34)
- Pneumocystis (39)
- Rarer Fungi (23)
-
PARASITES AND PROTOZOA
(44)
- Chagas (10)
- Protozoa (12)
- Strongyloides (14)
- Toxoplasmosis (12)
-
VIRUSES
(415)
- Adenovirus (17)
- Arboviruses (7)
-
CMV
(121)
- Cell-Mediated Immunity Assays (11)
- Clinical (55)
- Cytotoxic T-Lymphocytes (1)
- Epidemiology and Risk Factors (15)
- Letermovir (26)
- Maribavir (17)
- Preemptive Therapy (7)
-
COVID-19
(45)
- Diagnosis (3)
- Fungal superinfection (2)
- GUIDELINES (9)
- Infection Prevention (3)
- Positive Donors (6)
- Positive Recipients (5)
- Treatments (18)
- Vaccination (8)
- Hepatitis A (2)
- Hepatitis B (27)
- Hepatitis C (31)
- Hepatitis D (5)
- Hepatitis E (5)
- HHV-6 (24)
- HHV-8 (4)
- HIV (31)
- HPV (5)
- HSV (4)
- Influenza (17)
- Measles (22)
- Mpox (6)
- Norovirus (8)
- Parvovirus B19 (3)
- Polyomaviruses (32)
- Respiratory Viruses (32)
- RSV (18)
- VZV (17)
- WNV (2)
DIAGNOSTICS
- Advanced Diagnostics (23)
- Fungal diagnostics (41)
- Nuclear Medicine (7)
- Parasites (3)
- Procalcitonin (1)
- Viral diagnostics (1)
DRUGS AND THERAPIES
- Antibiotics (12)
- Antifungals (66)
- Antivirals (10)
- Cytotoxic T-lymphocyte therapy (8)
- Fecal Microbiota Transplantation (12)
- Phage therapy (4)
- Stewardship (57)
PREVENTION
- Infection Control (8)
- Safe Living (22)
- Travel (10)
- Vaccination (40)
SYNDROMES AND CONDITIONS
- Cirrhotics (12)
- CNS (3)
- Cytopenias (2)
- Diarrhea (13)
- Endovascular infections (12)
- Osteomyelitis and Diabetic Foot Infection (3)
- Pneumonia (11)
- Surgical Infections (3)
- UTI (32)
SOLID ORGANS AND MCSS
- Donor (43)
- Heart (14)
- Immunosuppression (14)
- Intestinal (2)
- Kidney (32)
- Liver (53)
- Lung (70)
- LVAD (30)
- Pancreas (5)
- PEDIATRIC (43)
- Recipient (5)
- Total Artificial Heart (1)
- Vascular Composite Allograft (2)
- Xenotransplantation (3)
HEME-ONC AND CELLULAR THERAPIES
- Biologics (45)
- BMT Basics (4)
- BMT Guidelines (14)
- BMT Noninfectious (10)
- BMT-specific ID (71)
- CAR-T (22)
- CAR-T Noninfectious (6)
- GVHD (6)
- Heme malignancies (4)
- Heme-onc prophylaxis (23)
- Neutropenia (40)
- PEDIATRIC (33)
- PTLD (24)
- TK inhibitors (12)
TRANSPLANT ID TRAINING
- AST (4)
- Career Development (2)
- Fungal (4)
- Training program (7)
PATIENT EDUCATION
- COVID-19 (13)
- Food (13)
- Hygiene (7)
- Mpox (5)
- Outdoor activities (3)
- PATIENT INFORMATION SHEETS (16)
- Pets (6)
- Safer living (22)
- Selected Infections (10)
- TB (10)
- Travel (6)
- Water safety (7)
- Workplace safety (3)
JOURNAL CLUB
- 2024 (2)